ऑस्ट्रेलिया - अंग्रेज़ी - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nj bradshaw t/a supreme pool products - chlorine present as lithium hypochlorite - algicide - spa | swimming pool | outdoor spa | spa pools - algae | bacteria

ऑस्ट्रेलिया - अंग्रेज़ी - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nj bradshaw - chlorine present as lithium hypochlorite - granular formulation - chlorine present as lithium hypochlorite mineral-chlorine active 350.0 g/kg - algicide - spa | swimming pool | outdoor spa | spa pools - algae | bacteria

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

bayshore pharmaceuticals llc (nj) - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 0.5 mg - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see precautions ) due to neuroleptic drugs (e.g., phenothiazine's). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients. because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see contraindications ).

मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bio-science marketing sdn. bhd. - cholecalciferol; protein-soy; sodium ascorbate; collagen hydrolysate; dl-alpha tocopheryl acetate; sodium hyaluronate; galactooligosaccharides; boswellia serrata gum extract; coral calcium -

मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

megalive biosciences sdn bhd - fish collagen; sodium hyaluronate; boswellia serrata gum extract; sodium ascorbate; vitamin d3 (cholecalciferol); dl-alpha tocopheryl acetate; galactooligosaccharides; coral calcium; curcuma longa extract (turmeric); hydrolyzed chicken eggshell membrane; soy protein; l-leucine; l-isoleucine; l-valine -

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

aarkish pharmaceuticals nj inc. - metolazone (unii: tz7v40x7vx) (metolazone - unii:tz7v40x7vx) - metolazone tablets are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. mykrox tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. a dose titration is necessary if mykrox tablets are to be substituted for metolazone in the treatment of hypertension. see package circular for mykrox tablets. usage in pregnancy the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. metolazone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see precautions). dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. there is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. if this edema produces discomfort, increased  recumbency will often provide relief. in rare instances, this edema may cause extreme discomfort which is not relieved by rest. in these cases, a short course of diuretics may be appropriate. anuria, hepatic coma or precoma, known allergy or hypersensitivity to metolazone.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

aarkish pharmaceuticals nj inc. - acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d), butalbital (unii: khs0az4jvk) (butalbital - unii:khs0az4jvk) - butalbital and acetaminophen tablets are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. caution in this regard is required because butalbital is habit-forming and potentially abusable. this product is contraindicated under the following conditions: • hypersensitivity or intolerance to any component of this product. • patients with porphyria. abuse and dependence: butalbital: barbiturates may be habit-forming: tolerance, psychological dependence, and physical dependence may occur especially following prolonged use of high doses of barbiturates. the average daily dose for the barbiturate addict is usually about 1500 mg. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication increases; tolerance to a fatal dosage, however, does not increase more than two-fold. as this occurs, the margin between an intoxication dosage and fatal dosage becomes smaller. the lethal dose of a barbiturate is far less if alcohol is also ingested. major withdrawal symptoms (convulsions and delirium) may occur within 16 hours and last up to 5 days after abrupt cessation of these drugs. intensity of withdrawal symptoms gradually declines over a period of approximately 15 days. treatment of barbiturate dependence consists of cautious and gradual withdrawal of the drug. barbiturate-dependent patients can be withdrawn by using a number of different withdrawal regimens. one method involves initiating treatment at the patient's regular dosage level and gradually decreasing the daily dosage as tolerated by the patient.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

aarkish pharmaceuticals nj inc. - acetazolamide (unii: o3fx965v0i) (acetazolamide - unii:o3fx965v0i) - for adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. acetazolamide tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. hypersensitivity to acetazolamide or any excipients in the formulation. since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. long-term administration of acetazolamide is contraindicated in patients with chronic non-congestive angle-closure glaucoma since it may permit organic closure of the angle to occur while the worsening glaucoma is masked by lowered intraocular pressure.

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - enalapril maleate -

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme australia pty ltd - etoricoxib -